Alex To

Dr. Alex To is Managing Member at Cross Current Research LLC.
He founded the firm in 2009.
He has over 20 years of experience in life sciences and healthcare investing derived from professional engagements on both the buy-side and the sell-side.
Dr. To started his career in life sciences and healthcare investments in 1991 when he joined Castle Group Ltd with responsibilities for financing early-stage biotechnology companies.
In 1994, he launched his successful career as an eminent sell side biotech analyst, leading biotech research for three major brokerage houses.
He first joined Donaldson Lufkin & Jenrette and established its biotech equity research group from the ground up.
He later joined Deutsche Bank and served as its global head of biotech research.
A year later, he moved to Credit Suisse First Boston to revamp its biotech research operations.
In 2001, he joined Duquesne Capital LLC as head of healthcare investments, where he was responsible for many successful investments in life sciences and healthcare services.
He also correctly called the downturn in biotech stocks in 2001 and created a profitable short portfolio.
He later founded Junction Capital, LP.
In 2006, he returned to sell side research and joined Natixis Bleichroeder, a French financial conglomerate, as a Managing Director and to head the firm’s biotech research.
He received an M.D.
from Boston University and an M.B.A. from the Wharton School of the University of Pennsylvania.